Boston Scientific, a leading medical-device maker, reported higher second-quarter results on Wednesday but simultaneously cut its full-year sales outlook as it begins a new restructuring plan that was announced earlier this week. The company posted a profit of $907 million, or 61 cents a share, compared with $797 million, or 53 cents a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were 86 cents, ahead of the 83 cents anticipated by analysts, according to Fact Set. However, the company now expects annual sales will grow 5.5% to 6.5%, down from 7% to 8.5% previously, reflecting the impact of the restructuring initiative.

Management indicated that the changes will position Boston Scientific for sustainable growth despite near-term headwinds, as the plan aims to streamline operations and improve long-term profitability. Investors reacted cautiously to the mixed results, with shares fluctuating in after-hours trading.